A review published in the World Journal of Pediatrics on June 23, 2026, presents a new framework for understanding and diagnosing a range of inflammatory conditions that mimic Behçet's disease (BD) in children. The concept, termed Behçet's spectrum disorders (BSD), was first introduced in 2020 but now receives a systematic, evidence-based classification designed to aid early recognition and genetic testing in pediatric patients.
Behçet's disease is a systemic vasculitis characterized by recurrent oral and genital ulcers, but its presentation in children is often partial or atypical, complicating diagnosis. Moreover, several monogenic autoinflammatory disorders produce nearly identical mucocutaneous and gastrointestinal symptoms yet require different treatments. This diagnostic overlap frequently leads to misdiagnosis and prolonged suffering. The new BSD framework, developed by researchers at Peking Union Medical College Hospital in Beijing, aims to address this challenge by grouping these conditions based on shared inflammatory pathways rather than solely on clinical symptoms.
The review, available at DOI: 10.1007/s12519-026-01035-4, proposes a two-tier classification. The "core BSD" tier includes monogenic diseases that directly disrupt NF-κB or JAK-STAT signaling, such as HA20 (caused by TNFAIP3 mutations), RELA haploinsufficiency, NFKB1 haploinsufficiency, and ELF4 deficiency. These conditions consistently feature recurrent mucocutaneous ulceration and converge on BD-relevant inflammatory circuits. The "peripheral BSD" tier encompasses polygenic or multifactorial entities like recurrent aphthous stomatitis (RAS), PFAPA syndrome, DADA2, and trisomy 8-associated disease, which exhibit partial clinical overlap or indirect pathway engagement but lack a defining monogenic driver.
By identifying NF-κB and JAK-STAT as central inflammatory hubs, the framework provides a rational basis for grouping these diverse disorders. The authors also delineate exclusion criteria to distinguish true spectrum members from phenotypic mimics such as LIG4 deficiency and IKBKG (NEMO) mutations. This mechanism-oriented lens does not replace existing BD diagnostic criteria but helps prioritize genetic testing in early-onset or atypical pediatric cases, potentially reducing diagnostic odysseys.
Clinically, the BSD framework enables earlier recognition of Behçet-like phenotypes and guides rational genetic testing, allowing targeted therapies—such as IL-1, TNF, or JAK inhibitors—for specific subsets. It also helps exclude non-spectrum mimics, avoiding unnecessary investigations. The framework is especially valuable in children with recurrent mouth ulcers, fever, and gut inflammation that do not fully meet BD criteria, providing a roadmap for what to test for and why.
The authors emphasize that these conditions are not the same disease but converge on the same inflammatory circuits. By shifting from symptom-based classification to stratified, mechanism-informed nosology, the BSD framework marks a paradigm shift that empowers pediatricians to move towards precision medicine. This research was supported by grants from the National Key R&D Program of China and the CAMS Innovation Fund for Medical Sciences, among others.
